AN2 Therapeutics, Inc. (ANTX) Misses Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts ANTX Hot Sheet
Join SI Premium – FREE
AN2 Therapeutics, Inc. (NASDAQ: ANTX) reported Q1 EPS of ($0.35), $0.10 worse than the analyst estimate of ($0.25).
For earnings history and earnings-related data on AN2 Therapeutics, Inc. (ANTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo says positioning rotation over, time to pick stocks
- FLEX Ltd (FLEX) PT Lowered to $150 at BofA Securities, 'pullback overdone'
- Safran SA (SAF:FP) (SAFRF) PT Lowered to EUR370 at Bernstein SocGen Group
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
